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Abstract:  
Down syndrome (DS) is caused by three copies of human chromosome 21 (Hsa21) and results 
in phenotypes including intellectual disability and skeletal deficits. Ts65Dn mice have three 
copies of ~50% of the genes homologous to Hsa21 and display phenotypes associated with DS, 
including cognitive deficits and skeletal abnormalities.  DYRK1A is found in three copies in 
humans with Trisomy 21 and in Ts65Dn mice, and is involved in a number of critical pathways 
including neurological development and osteoclastogenesis.  Epigallocatechin-3-gallate 
(EGCG), the main polyphenol in green tea, inhibits Dyrk1a activity. We have previously shown 
that EGCG treatment (~10mg/kg/day) improves skeletal abnormalities in Ts65Dn mice, yet the 
same dose, as well as ~20mg/kg/day did not rescue deficits in the Morris water maze spatial 
learning task (MWM), novel object recognition (NOR) or balance beam task (BB).  In contrast, a 
recent study reported that an EGCG-containing supplement with a dose of 2-3 mg per day (~40-
60mg/kg/day) improved hippocampal-dependent task deficits in Ts65Dn mice.  The current 
study investigated if an EGCG dosage similar to that study would yield similar improvements in 
either cognitive or skeletal deficits.  Ts65Dn mice and euploid littermates were given EGCG [0.4 
mg/mL] or a water control, with treatments yielding average daily intakes of ~50 mg/kg/day 
EGCG, and tested on the multivariate concentric square field (MCSF)—which assesses activity, 
exploratory behavior, risk assessment, risk taking, and shelter seeking—and NOR, BB, and 
MWM.  EGCG treatment failed to improve cognitive deficits; EGCG also produced several 
detrimental effects on skeleton in both genotypes. In a refined HPLC-based assay, its first 
application in Ts65Dn mice, EGCG treatment significantly reduced kinase activity in femora but 
not in the cerebral cortex, cerebellum, or hippocampus.  Counter to expectation, 9-week-old 
Ts65Dn mice exhibited a decrease in Dyrk1a protein levels in Western blot analysis in the 
cerebellum.  The lack of beneficial therapeutic behavioral effects and potentially detrimental 
skeletal effects of EGCG found in Ts65Dn mice emphasize the importance of identifying 
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dosages of EGCG that reliably improve DS phenotypes and linking those effects to actions of 
EGCG (or EGCG-containing supplements) in specific targets in brain and bone. 
 
Keywords: Key words: Trisomy 21, Down syndrome, EGCG, mouse model, bone, cognition 
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1. Introduction 
Down syndrome (DS), the leading genetic cause of intellectual disability, is caused by 
the three copies of human chromosome 21 (Hsa21) [1, 2]. DS has an incidence of ~1 in 700 live 
births and results in phenotypes that affect the central nervous and skeletal systems in all 
humans with DS [3-5]. Cognitive and neurodevelopmental disabilities are characterized by 
deficiencies in hippocampal-dependent memory functions, reduced size of hippocampus and 
cerebellum, reduced dendritic and axonal number and volume, early occurrence of Alzheimer 
disease, motor dysfunction and altered hippocampal synaptic plasticity [6-9]. Humans with DS 
also exhibit skeletal structures that are generally smaller than normal and with reduced bone 
mineral density (BMD) that can lead to osteoporosis. [10-12]. 
Mouse models have been used to study the complex genotype-phenotype relationship 
associated with DS, assessing both the role of a chromosomal region or specific genes on the 
pathogenesis of DS and possible therapeutic interventions [13-16]. The Ts(1716)65Dn (Ts65Dn) 
mouse model is the most extensively studied and widely used animal model of DS and captures 
several behavioral and skeletal defects that are seen in humans with DS [13, 17-20]. We and 
others have shown that Ts65Dn mice exhibit behavioral and functional neurological deficits, 
including a variety of deficits on learning and memory tasks [20, 21]. Ts65Dn mice show deficits 
in novel object recognition (NOR) and spontaneous alternation [6], show increased locomotor 
activity [22, 23], have deficits in the Morris water maze (MWM) place learning (using the hidden 
platform version) and (under some testing conditions) on the cued task of the visible platform 
version [20, 23, 24], have gait abnormalities [25] and motor coordination deficits [23]. For 
skeletal parameters in DS mouse models, we and others have identified significant deficits in 
BMD, trabecular bone parameters (thickness, separation and number) and cortical bone 
measures in Ts65Dn mice compared to euploid control mice [17]. Significant deficits in mineral 
apposition rate (MAR), bone formation rate (BFR), and strength properties in trisomic mice 
compared to controls were also observed [17, 26, 27].   
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The gene for Dual-specificity tyrosine phosphorylation-regulated kinase 1a (DYRK1A) is 
found in three copies in humans with DS [28] and is thought to play a key role during CNS 
development and osteoclastogenesis.  Notably, adverse effects may be present both with 
increased and decreased DYRK1A expression levels [29-31].  Dyrk1a protein levels were found 
to be ~1.5 fold higher than euploid control levels in the cortex, cerebellum and hippocampus of 
5-6 month old Ts65Dn mice [32] and in brain of 7-8 month old Ts65Dn mice [33].  However, 
other studies have reported no differences in brain homogenate Dyrk1a mRNA levels in 5-
month-old Ts65Dn mice [34].  In post-mortem cases of individuals with DS (age groups of 10-30 
years and 40+ years old), Western blot analysis found that DYRK1A protein levels were 
increased 1.5 fold above age-matched controls in the frontal, temporal, occipital, and cerebellar 
cortices and in cerebral and cerebellar white matter; however, brains from infants (1-3 years old) 
in this study did not have significantly increased DYRK1A protein expression [33]. These studies 
support the growing possibility that Dyrk1a overexpression is both spatially and temporally 
regulated during development in DS.  Furthermore, only a few studies have reported levels of 
Dyrk1a kinase activity; 15-month-old Ts65Dn mice exhibited increased Dyrk1a kinase activity in 
brain tissue as compared to controls [35], whereas another study reported no differences in 
Dyrk1a kinase activity in cerebellum hippocampus and cerebral cortex between 6 week old 
Ts65Dn and control mice [23].  Understanding functional Dyrk1a kinase activity differences 
between Ts65Dn and control mice at specific developmental periods in specific tissues is a 
necessary component for assessing the efficacy of pharmacotherapies targeting Dyrk1a. 
Epigallocatechin-3-gallate (EGCG) is the most prevalent polyphenol found in green tea 
[36] and has been tested for therapeutic effects in various pathologies, including anti-cancer 
activity, anti-oxidant activity, anti-bacterial activity, anti-allergic activity and anti-inflammatory 
activities [37-41]. EGCG is a small molecular inhibitor of DYRK1A activity and is thought to 
function by binding to the ATP binding domain of the protein thereby inhibiting its kinase activity 
[42, 43]. EGCG, either alone or in supplements containing EGCG, has been tested as a 
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potential therapy in mouse models of DS [23, 26, 44-48] and in humans with DS [45, 49, 50].  In 
one recent study [45] trisomic mice were given an EGCG-containing supplement (Life 
Extension® Mega Green Tea Extract, Lightly Caffeinated) in drinking water that was reported to 
deliver 2-3 mg of EGCG per day per mouse (i.e., a daily dosage of ~80-120 mg/kg [for a 25 g 
mouse] that would yield a final effective dosage of ~40-60 mg/kg per day after accounting for 
the known degradation of EGCG [23, 44]).  This dosage rescued acquisition of spatial 
navigation and normalized thigmotaxic behavior in the MWM, and improved novel object 
recognition (NOR) discrimination ratios [45].  Those findings stand in contrast with studies in our 
laboratory that used either a three-week or a seven-week treatment of pure EGCG 
(concentration of 0.124 mg/mL) beginning in early adolescence that delivered a dosage of either 
~10 mg/kg/day (EGCG in water) or ~20 mg/kg/day (stabilized EGCG in acidified water and 
corrected for degradation). The 10 mg/kg/day dosage improved skeletal deficits including 
femoral BMD, percent trabecular bone volume, trabecular number and trabecular thickness in 
Ts65Dn mice [26], but neither the 10 nor the 20 mg/kg/day dosage improved performance in the 
MWM, NOR, or balance beam motor coordination task [23]. 
The goal of the current study was to test whether the lack of EGCG effects in our 
previous study [23], compared to the improved phenotypes with the EGCG-containing 
supplement found by De la Torre and colleagues [45], may have been be due to the lower 
dosages of EGCG.  The current study administered a dosage of pure EGCG intended to 
approximate the EGCG dosage that we determined was delivered in the De la Torre et al. [45] 
study (~50 mg/kg/day), which includes our correction for the ~50% degradation of EGCG that is 
known to occur when EGCG is dissolved in the drinking water [23, 44]. Thus, Ts65Dn mice 
were administered either EGCG [0.4mg/mL, stabilized in acidified water], which yielded a target 
average daily intake of ~50 mg/kg/day after correction for known degradation, or acidified water 
alone. Given that the current study used a higher concentration of EGCG (0.4 mg/mL) for a 
longer duration (7 weeks) than our previous study (0.124 mg/mL for 3 weeks) that showed that 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
EGCG improved bone phenotypes [26], an additional goal was to determine whether this higher 
dosage for longer duration would yield more extensive improvement in skeletal deficits than 
previously observed.  The current study was also the first to employ the Multivariate Concentric 
Square Field (MCSF) in mouse models of DS, a behavioral task originally developed by 
Meyerson and colleagues that assesses patterns of activity and exploration in a complex novel 
environment, and has been shown to identify distinct behavioral phenotypes in rodent models, 
quantify locomotor activity, exploratory behavior, risk-taking, risk assessment, and shelter 
seeking, [51].  MCSF appears to be well suited to study behavioral phenotypes associated with 
neurodevelopment disorders given prior results from various rat and mouse models indicating 
its sensitivity to effects of traumatic brain injury [52], early life maternal separation stress [53], 
and disparities in lines of rodents selectively bred for differences in voluntary alcohol drinking 
[54].  Another key goal of this study was to determine Dyrk1a protein levels using Western blot 
analysis and to quantify kinase activity using a modified HPLC-based assay that has been 
suggested to measure Dyrk1a-related activity [55]. To our knowledge, this is the first report of 
quantification of Dyrk1a levels and kinase activity in specific brain regions and bone assessing 
whether EGCG treatment altered Dyrk1a protein and activity in a manner that was linked with 
changes in behavioral and skeletal DS-related phenotypes. 
 
2. Materials and Methods 
2.1 Animals 
All animals were housed in the secure AAALAC-accredited Science Animal Resource 
Center facility in the IUPUI School of Science.  Ts65Dn females (approximately 50% B6 and 
50% C3H background with small trisomic marker chromosome) were bred to B6C3F1 males 
(both obtained from the Jackson Laboratory [Bar Harbor, ME]) in rooms with a standard 12:12 
light:dark cycle to generate the mice used in the study. Only male mice were used due to the 
subfertile nature of Ts65Dn mice, making it necessary to retain Ts65Dn females as breeders for 
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colony maintenance. On postnatal day (PD) 21, the male mice were weaned and single-housed 
in standard mouse cages, and randomly assigned to the different treatment groups. The 
vivarium containing the mice undergoing treatment was maintained on a reverse 12:12 
light:dark cycle with white light off between 0800-2000, during which time only red light was 
present.  Experiments with animals were carried out in accordance with the NIH Guide for the 
Care and Use of Laboratory Animals and received prior approval from the IACUC committee at 
IUPUI (SC213R and SC255R). 
 
2.2 EGCG/Water Treatment 
EGCG (>95% purity, as determined by LC/MS analyses [44]) was prepared by making a 
stock solution of 15 mg/mL EGCG in phosphate buffered saline (PBS). Treatments were 
delivered via the drinking water in a concentration of 0.4 mg/mL EGCG, prepared by diluting the 
stock solution in tap water, and pH balanced (5-5.5) by slowing adding phosphoric acid 
(approximately 100μL/100mL tap water).  Treatments started on PD 24, usually 3 days after 
weaning.  Treatments (EGCG or acidified water control) were placed in drinking tubes and the 
mice were allowed access ad libitum to its designated treatment as its sole source of fluid. The 
volumes consumed and animal weights were recorded every 48 hours at the time the 
treatments were changed.  Treatments continued throughout the duration of behavioral testing, 
which ended on PD 68.  
 
2.3 Behavioral Timeline 
Figure 1 shows the behavioral timeline for the study.  Starting on PD 43, mice were 
handled by the experimenter in the vivarium for two consecutive days.  Behavioral testing began 
with the MCSF test on PD 45-PD 46, followed by three consecutive days of NOR (PD 47-PD 
49).  After two days of rest, the mice were trained for three consecutive days on the balance 
beam task (PD 52-PD 54), followed by the MWM task from PD 57-PD 64.  A final NOR task was 
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administered on PD 65-PD 67.  The NOR and MWM tasks were all conducted using previously 
published protocols [23]. On PD 68, mice were euthanized using isoflurane followed by cervical 
dislocation.  Tissue from the cerebellum, cerebral cortex and hippocampus was rapidly 
dissected, snap frozen, and stored at -80°C.  The mouse carcass was stored at 4°C, and in the 
following week, femurs were dissected, wrapped in PBS-soaked gauze and frozen at -20°C until 
analysis was performed. 
[Insert Figure 1 here] 
 
2.3.1 Multivariate Concentric Square Field (MCSF) 
 Mice were tested in the MCSF on PD 45 and 46.  The MCSF apparatus, adapted from 
Ekmark-Lewén [52], is a complex, multi-compartment novel environment in which animals may 
move around and explore freely among various compartments and areas, including ones that 
are open, elevated, or sheltered [see Supplemental Figure 1 for image].  The MCSF design 
consists of an outer square field [70 cm x 70 cm x 26 cm (high)] that encloses a smaller interior 
center square field [41 cm x 41 cm x 25 cm (high)] centered within the larger field.  The center 
square field contains a demarcated circular zone [center circle: 16 cm diameter] to record 
activity in the center of the MCSF.  Three of the sides of the center square contain circular 
openings (8 cm) that permit entry into one of three corridors that make up three sides of the 
perimeter of the MCSF:  the north corridor (containing an entrance to the slope and bridge), the 
south corridor (containing an entrance to the dark corner room (DCR), and the west corridor 
(open sloped incline to the hurdle that contains two, 2.5-cm holes with photocells underneath 
the holes to measure nose pokes). The fourth side of the MCSF perimeter is side-illuminated by 
a fluorescent light (approximately 320 lux) and contains an elevated bridge constructed of 
stainless steel (10 mm) wire-mesh that is elevated 177 cm above the floor and is accessible 
from the north corridor.  The DCR is enclosed and covered, and can only be accessed through 
the south corridor.   
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For each session, the animal was placed in the center zone facing the wall with no 
openings; and its activity was video recorded for each 20-minute session in dim light (15-20 lux) 
in all areas except for the dark corner room (1-2 lux) and the lighted bridge area (320 lux). The 
MCSF was thoroughly cleaned between testing sessions with 70% ethanol.  Photocell counts 
and fecal boli were recorded after each 20-minute session by the experimenter. 
All sessions were scored by three independent observers blind to experimental 
treatment and genotype.  Behavioral measures were obtained using The Observer XT Version 8 
software (Noldus Information Technology, Wageningen, The Netherlands), and included 
measures of frequency of entries, duration, duration per visit, and latency to initial visit for each 
defined location within the MCSF. Measurements of rearing were not available due to unreliable 
identification of defined rearing events in video playback.  The three scorers’ results were 
averaged to obtain the score value that was used for each animal. The correlation of scores 
across all measures across the three raters was r >+0.99. The full listing of all behavioral 
measures obtained from the scoring is provided Table 1.  
Meyerson and colleagues have developed rank-order analytic approaches to data from 
the MCSF that identify categories of behavioral phenotypes, using the sums of ranks of 
designated measures that were combined to form identified categories of behavioral activities in 
the MCSF.  These combined measures (that they refer to as “trend analysis”) reflect common 
underlying functions expressed in different behaviors or in different behavioral strategies across 
the complex environment of the MCSF, classified as general activity; exploratory behavior, risk 
assessment, risk taking and shelter seeking [56].  The value of the MCSF with its ethological 
behavioral dimensions was demonstrated in that study by showing that the behavioral trends 
extracted from the MCSF were more sensitive to anxiolytic effects of diazepam than the 
standard measure of the elevated plus maze. We used similar subsets of measures modified 
from those of Meyerson [56], defining the five behavioral categories in the following way (see 
Table 1):  “Total entries”—a measure of locomotor activity—included the frequency of entries 
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into the hurdle, DCR, slope, bridge, center circle and center square, along with the summed 
frequency of entries into the three corridors (TotCorr).  ”Exploratory behavior” included the total 
duration of time spent in the hurdle, the duration per visit to the hurdle, total photocell counts, 
latency to initial slope visit, latency to initial hurdle visit, and the duration per visit to the center 
square.  ”Risk assessment” included the latency to leave the center square, the duration per 
visit to the slope, as well as the difference between latency to initial bridge visit minus the 
latency to initial slope visit.  “Risk-taking” included the total duration of bridge visits, duration per 
visit to the bridge, the total duration of center circle visits, and duration per visit to the center 
circle.  “Shelter seeking” included the frequency of DCR entries, the total duration of DCR visits, 
the duration per visit to the DCR, and the latency to initial visit to the DCR.     
[Insert Table 1 here] 
 
2.3.2 Novel Object Recognition (NOR) 
The NOR task was performed over three consecutive days.  For the first day, animals 
underwent habituation, in which they were placed individually inside the painted plywood test 
box and allowed to explore the environment for 15 minutes. On the next day (object exposure 
day), two matching objects (8.5-11.0 cm tall; 3.0-4.5 cm base) were placed near the NW and SE 
corners of the box, approximately 5 cm from the wall, and each mouse was placed in the middle 
of the arena and allowed 15 minutes to explore the arena and objects.  On the final day (test 
day) one object from the previous day and one novel object were placed inside and the mice 
were given 15 minutes to explore. Activity on each day was recorded with video tracking using 
ANYMAZE software (Stoelting Co, Wooddale, IL).  The discrimination ratios of the time 
exploring each object on the test day were determined using the following formula: 
discrimination ratio (%) = [(time exploring novel object- time exploring familiar object) / total 
exploration time for both objects] * 100.         
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2.3.3 Balance Beam Task 
 The balance beam task was performed over three consecutive days.  The apparatus 
consisted of 1 m painted wooden beams with a surface width of either 19 mm, 12 mm, 9 mm or 
6 mm, situated 58 cm above the floor.  A black goal box was located at the end of the beam, 
and contained bedding from the animals’ cage.  On the first day, a cohort of mice (2-5 mice) 
was brought into the testing room each mouse was trained to walk from one side of the 19mm-
wide beam to a black goal box, starting at varying distances from the box.  On the second day, 
the mice were trained to cross the entire length of the 12 mm-wide beam without stopping on 
three consecutive trials. On the third day, the mice were tested on three trials each on the 12 
mm-, 9 mm- and 6 mm- wide beams.  A Logitech camera at the opposite end of the goal box 
recorded these trials. The video records of the test day were scored by three trained 
independent scorers, blind to genotype or treatment, to quantify the number of hind paw slips, 
defined as either the left or right hind paw entirely missing the beam.   
 
2.3.4 Morris Water Maze Place Learning Task (MWM) 
 The Morris water maze (MWM) utilized a 125 cm (diameter) white tank filled to within 25 
cm of the rim with water (24-26ºC) clouded with white tempera paint.  Training consisted of 7 
days of acquisition, followed by a single probe trial given 24 hours after the last training day.  
The acquisition training consisted of four trials a day, at random starting positions for each trial.  
In each trial, the animal was allowed to swim for 60 seconds or until it located and climbed onto 
the platform.  If the platform was not found in the 60 seconds, the experimenter gently moved 
the mouse to the platform.  For acquisition trials, video tracking and data collection software 
(HVS Image, Mountain View, CA, USA) was used to obtain measures of latency to find the 
platform path length (cm), time spent within 25.4 cm of the wall (thigmotaxis), time spent not 
moving (floating), and swimming speed (cm/sec).  Mice were tested in cohorts of three to four, 
with an inter-trial interval of approximately 3-4 minutes.  Twenty-four hours after the last training 
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day, the mice were given a 60-sec “probe trial” in which the platform was removed and the 
animal’s search path was recorded and scored for spatial biases using four superimposed 
virtual counting discs (27 cm diameter) in the center of each quadrant (over the four possible 
platform positions used for training).  Probe trial measures included time spent in, latency to 
enter, and numbers of crossings through each of the four virtual counting discs.  These 
measures were used to quantify the spatial distribution of the search strategy of each animal by 
a priori comparisons of the time spent in the target location (trained during acquisition) to the 
mean time spent in the three non-target locations.  
 
2.4 Micro Computed Tomography (µCT) 
 The left femora were thawed to room temperature and then scanned using a high-
resolution μCT system (SkyScan 1172, Bruker microCT, Belgium). Daily calibrations were 
performed prior to scanning the bones using two cylindrical hydroxyapatite phantoms (0.25 and 
0.75 g/cm
3
 calcium hydroxyapatite).  The distal and midshaft portion of the femur were scanned 
using the following parameters: voltage 60 kV, resolution 6 µm, binning mode 2 k and filter Al 
0.5 m. Scans were reconstructed using NRecon and CTan software (SkyScan, Bruker microCT, 
Belgium).  After scanning, bones were wrapped in PBS-soaked gauze and stored at -20°C until 
mechanical testing.  Bone mineral density (BMD) was calculated using the hydroxyapatite 
phantoms as a standard. The trabecular, and cortical analysis was performed using a previously 
published protocol [57].  For cortical bone analysis, a standard site was chosen at 60% of the 
bone’s total length away from the distal growth plate.  Seven transverse slices were generated 
from the above site and cortical properties were obtained using a custom Matlab code 
(MathWorks, Inc. Natick, MA).  The regions of interest for femora were kept constant across 
genotype and treatment groups. Trabecular analysis was performed on the distal metaphysis 
with a region of interest defined as 10% of total bone length, starting at the proximal end of the 
distal growth plate then extending proximally. The region of interest was auto-segmented to only 
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include trabecular bone using a custom Matlab code [57]. Two bones were excluded from the 
cortical analysis because of extreme non-normality.  
 
2.5 Mechanical Testing 
Following µCT, the mechanical properties of the femur were determined in 3-point 
bending (ElectroForce 3200; Eden Prairie, MN USA). The left femora were thawed to room 
temperature, and tested in the AP direction (anterior surface in tension). The loading span was 
set at 6 mm and a preload of 0.5 N was applied to the midpoint of the bone to establish contact. 
Once preloaded, the bone was monotonically tested to failure at a displacement rate of 0.025 
mm/sec.  Mechanical data from five bones were not obtained due to technical errors and 
therefore were excluded from the analysis (1 Eu+Water, 1 Eu+EGCG, 1 Ts+Water, 2 
Ts+EGCG). 
 
2.6 High Performance Liquid Chromatography (HPLC) Kinase Activity Assay 
Protein was isolated from frozen (snap frozen then stored at -80°C) hippocampus, 
cerebellum, cerebral cortex, and femurs utilizing a protocol adapted from previous studies [58, 
59]. The isolated protein was quantified using the Bradford assay to determine the concentration 
before proceeding with a HPLC-based kinase activity assay.  The protein kinase activity was 
analyzed using a previously published protocol (with modifications) that was reported to quantify 
Dyrk1a activity in  trisomic mouse models [55].  Briefly, protein samples (~100 µg) were pre-
incubated for 1 minute in a 37ºC water bath with a 5-carboxyfluorescein tagged Woodtide 
peptide (2 mg/mL) and kinase buffer.  ATP (1 mM) was added to start the reaction and all 
samples were incubated in a 37ºC water bath for 30 minutes. Following incubation, the reaction 
was stopped by the addition of HClO4 (15%) and centrifuged at 4
 ºC for 10 minutes at 14,655 g 
to remove any sediments.  Blanks and the samples were placed in conical glass inserts inside 
2mL autosampler vials for analysis on the Agilent 1260 HPLC. Separation was performed using 
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initial conditions of 85% H2O with 0.1% formic acid (solvent A) and 15% acetonitrile with 0.1% 
formic acid (solvent B) held for 1 minute, followed by a stepwise gradient ending with 5% 
solvent A and 95% solvent B over 11 minutes. FAM-Woodtide fluorescence was measured 
using a fluorescence detector with an excitation wavelength of 485 nm and an emission of 530 
nm.  The peak height and retention time were used to determine the area under the curve for 
the p-FAM-Woodtide and FAM-Woodtide. Results were analyzed using OpenLab CDS 
Chemstation software.  
 
2.7 Western Blot to Quantify Dyrk1a Protein 
Isolated protein lysates (20µg) from the three brain regions (there was not sufficient 
femur protein to detect Dyrk1a protein) were resolved electrophoretically on polyacrylamide gels 
(Bolt 4-12% Bis Tris Plus Gels), then transferred to PVDF membranes.  Membranes were 
blocked in 5% milk in Tris Buffered Saline with 0.1% Tween 20 (TBS-T), incubated overnight at 
4°C in primary antibodies diluted in 5% milk-TBS-T as follows: rabbit anti-DYRK1A antibody, 
1:500 (A303-802A, Bethyl Laboratories); mouse anti-beta-actin, 1:5000 (A2228, Sigma Aldrich), 
and labeled with donkey anti-rabbit IgG AlexaFluor 790 and donkey anti-mouse IgG AlexaFluor 
680 secondary antibodies (1:10,000, Jackson Immunoresearch).  Fluorescence was detected 
using a LI-COR CLx Imager.  Each membrane contained at least three controls (Eu+Water) for 
a specific brain region (cerebellum, cerebral cortex, and hippocampus).  Dyrk1a was normalized 
to actin controls and each normalized value was expressed as a ratio relative to the mean of the 
controls ran that were run within each blot. A total of eight independent blots contributed to the 
final data set. 
 
2.8 Statistical Analyses 
For the MCSF, the mean of each of the individual measures (e.g., latency to initial visit, 
duration, frequency, and duration per visit) was generated from the three independent observer 
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scores, and scores for each of the five behavioral categories were tabulated as shown in Table 
1.  Five of the Ts65Dn mice with small body size were able to enter into the port with the 
photocell counter and remain there for extended periods of time, so their data were excluded 
from the MCSF analysis (2 Ts+Water; 3 Ts+EGCG). The primary hypothesis involved detection 
of interactive effects of treatment with genotype (i.e., normalization of Ts65Dn phenotypes with 
EGCG), so our approach was to apply parametric ANOVA approaches with the emphasis on 
identifying outcomes showing significant treatment x genotype interactions, though all significant 
ANOVA terms were identified.  The total entries data (summed across the six included 
measures) constituted an underlying continuous variable and was distributed normally in all but 
one group (Shapiro-Wilk’s W test), so those sums were analyzed directly with a 3-way repeated 
measures ANOVA with genotype and treatment as grouping factors and day as a repeated 
measure.  The other four behavioral categories (risk-taking, risk assessment, shelter seeking 
and exploratory behavior) involved measures using different scales (e.g., frequency; duration) 
and individual measures were often not normally distributed.  Consequently, the data for each 
contributing measure (see Table 1) were first rank ordered, then the ranks for the measures 
contributing to a category were summed across the measures for each animal to provide a 
single summed score for the animal for each category.  To assure that rank ordering reflected 
increasing amount of the target behavior in the category, the subject means of each measure 
were ranked in ascending order, except for the following which were ranked in descending order 
a) latency to leave the center (long latencies mean assessed risk is low), b) latency to initial 
slope visit (long latencies mean exploratory behavior is low), c) latency to initial hurdle visit (long 
latencies mean exploratory behavior is low), and d) latency to initial DCR visit (long latencies 
mean shelter seeking is low).  The summed scores of subject ranks for each of these four 
categories formed a continuous underlying variable for each category and were normally 
distributed within each group in all but two cases (Shapiro-Wilk’s W test), so the data were then 
analyzed with a 3-way mixed measures ANOVA with genotype and treatment as grouping 
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factors and day as a repeated measure. In the absence of main or interactive effects of day, 
follow-up analyses of simple main effects of genotype or treatment were performed on the data 
collapsed across day, Fisher's least significant difference (LSD) tests (α=0.05) were used for 
post hoc comparisons between individual groups to follow up significant ANOVA main effects or 
interactions of genotype and treatment.   
The discrimination ratios from the NOR data on the test day, were analyzed with a two-
way ANOVA using genotype and treatment as a between subjects factor.  Fisher's LSD tests 
(α=0.05) were used for post hoc comparisons between individual groups to follow up significant 
ANOVA main effects or interactions.   
For the MWM, the average daily latency and path length over the seven days of training 
were analyzed using a mixed ANOVA with day as a repeated measure and genotype and 
treatment as between-group factors.  For each mouse, the daily latency and path length were 
typically strongly correlated across the acquisition period. However, ten of the 70 subjects 
trained in the MWM failed to perform the swimming task well across days (e.g., spending >20 
sec per trial floating), such that latency and path length were poorly correlated.  In those cases, 
(where the correlation was <0.2), the animals were excluded from both acquisition and probe 
MWM analyses (3 Eu+Water, 2 Eu+EGCG, 3 Ts+Water, 3 Ts+EGCG).  For the probe trial, the 
time spent in the virtual target disc (in the target quadrant) and the average time spent in the 3 
equivalent virtual non-target discs (in the other 3 quadrants) were analyzed using a mixed 
ANOVA with treatment group and genotype as between-group factors and disc location (target 
vs non-target) as a repeated measure.  For the probe, four of the mice that had met the 
performance criteria during acquisition nevertheless floated for >26 seconds during the 60 
second probe trial (> 43% of the trial) so they were excluded from the probe trial analysis (1 
Eu+EGCG, 1 Ts+Water, 2 Ts+EGCG).  
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The number of paw slips on the balance beam was analyzed using a mixed ANOVA with 
treatment group and genotype as between-group factors, and beam width (12 mm, 9 mm and 6 
mm) as a repeated measure.   
For skeletal measurements, many of the measures were not normally distributed and 
transformations were made to achieve normality.  Where the transformed measures did not 
achieve normality, non-parametric tests were used.  The bone parameters (Tables 3 and 4) 
were analyzed with a two-way ANOVA using genotype and treatment as a between subjects 
variable. 
 
3. Results 
3.1 Growth and EGCG intake 
 As shown in Table 2, Ts65Dn mice had significantly lower body weights and slower 
growth as compared to euploid mice over days [day x genotype interaction, F(21,1260)=6.96, 
p<0.001].  Both euploid and trisomic mice decreased their daily EGCG consumption (per kg 
body weight) over time [main effect of day, F(15,405)=13.43, p<0.001]; however, there were no 
significant differences in EGCG consumption between the euploid and trisomic mice (Table 2). 
[Insert Table 2] 
3.2 MCSF  
Total entries. Both euploid and trisomic mice increased the frequency of total entries 
from day 1 to day 2 [main effect of day, F(1,54)=46.36, p<0.001] (see Figure 2), However, the 
trisomic mice showed significantly greater increases in total entries from day 1 to day 2, 
[genotype x day interaction, F(1,59)=7.71, p=0.008].  A two-way ANOVA on total entries change 
scores (day 2-day 1) confirmed the significantly larger increase in the Ts65Dn mice [main effect 
of genotype, F(1, 54)=7.7, p=0.008)].  Follow-up paired sample t-tests comparing day 1 and day 
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2 total scores indicated both Ts65Dn groups significantly increased total entries across days 
whereas for the euploid groups, only the water group significantly increased total entries.   
[Insert Figure 2] 
Exploratory behavior.  There were no significant main or interactive effects found in the 
2-way ANOVA on exploratory behavior (see Supplemental Table 1).  
Risk Assessment. The 3-way ANOVA yielded only a main effect of genotype [F(1, 
54)=6.3, p=0.015], with no main or interactive effects of treatment or day, indicating that overall 
the Ts65Dn mice had higher levels of risk assessment across days compared to the euploid 
mice. In the post hoc analysis (as shown in Figure 2b), the increased risk assessment of the 
Ts65Dn mice was mainly due to the significantly higher levels of the Ts65Dn group given EGCG 
compared to either euploid group (p<0.01). 
Risk-taking behavior.  The 3-way ANOVA yielded a significant genotype x treatment 
interaction [F(1,54)=4.07, p=0.048], with no main or interactive effects of day. As shown in 
Figure 2c, EGCG treatment produced opposite effects in the two genotypes, increasing risk 
taking in euploid mice but decreasing it in Ts65Dn mice. 
Shelter Seeking behavior. There were no significant main or interactive effects found in 
the 2-way ANOVA on shelter seeking behavior (see Supplemental Table 1). 
There were no significant main or interactive effects found in the 2-way ANOVA on fecal 
counts (see Supplemental Table 4). 
 
3.3 NOR 
There were no significant main or interactive effects of genotype or treatment in the 
discrimination ratios for either NOR test.   
 
3.4 Balance Beam 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
There were no significant main or interactive effects of genotype or EGCG treatment on 
the balance beam task, though there was a trend for the Ts65Dn-water group to commit more 
paw slips than the euploid-water group.  Both groups made more paw slips as the beam width 
decreased [main effect of width, F (2,116) = 100.84, p<0.001] (Supplemental Table 2). 
 
3.5 Morris Water Maze 
 Across training days, all groups showed significant reductions in path lengths (see 
Figure 3a) and latencies to find the platform (Figure 3b) [main effect of day, F(6,276) = 10.2, 
p<0.001 for path length; F(6,276) = 7.32, p=<0.001 for latencies].  The Ts65Dn mice were 
significantly impaired in acquisition relative to control mice, as confirmed by the day x genotype 
interaction both for path length [F(6,276)=2.28, p=0.037] and for latency [F(6,276) = 2.2, 
p=0.041]. 
There was a main effect of day on swimming speed [F(6,276) =11.98, p<0.001], 
however there were no significant effects of genotype or treatment on swimming speed, 
indicating that the euploid and trisomic groups did not differ on this measure of swimming 
performance.  Mice receiving EGCG displayed higher levels of thigmotaxic behavior (Figure 3c) 
than those receiving water [main effect of treatment, F(6,276)=2.24, p=0.039], and thigmotaxic 
behavior generally declined over days [main effect of day, F(6,276)=3.65, p=0.002], most 
prominently in the euploid-water group.  In addition, trisomic as compared to euploid mice 
displayed significantly less reduction in floating behavior (Figure 3d) over the course of 
acquisition [day x genotype interaction, F(6,276)= 2.64, p=0.017]. 
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 [Insert Figure 3] 
For the probe trial (see Figure 4), all groups had a preference for the target quadrant 
[main effect of location (1,42)= 32.84, p= <0.001], and there were no statistically significant main 
or interactive effects of genotype or treatment.  A priori paired t-tests comparing time in target 
vs. non-target virtual discs showed that the euploid groups spent significantly more time in the 
target disc (p<0.05), but the differences for the trisomic groups did not reach significance. 
Nevertheless, there were no significant differences in time spent in the target quadrant among 
the four groups.  There were no significant main or interactive effects of genotype or treatment 
on the amount of time spent floating, swimming speed, path length or the amount of time in 
thigmotaxis during the probe trial (see Supplemental Table 3). 
[Insert Figure 4] 
3.6 Micro CT Analysis of Femora  
In the cancellous bone of the distal femoral metaphysis, there were several effects of 
trisomy but no impact of EGCG treatment (Table 3). Bone volume fraction (BV/TV) was 
significantly lower in trisomic as compared to control mice [F(1,43) =6.23, p=0.017]. This 
decrease was likely driven by a significant decrease in trabecular number [F(1,43) =6.23, 
p=0.016] coupled with a significant increase in trabecular separation [F(1,43) =9.07, p=0.004] in 
the trisomic as compared to euploid femora.  
For cortical geometry, the Ts65Dn as compared to euploid mice had significantly lower 
total cross sectional area [F(1,42) =9.92, p=0.005], cortical area [F(1,42) =11.99, p=0.001] and 
cortical thickness [F(1,42) =9.00, p=0.005] of the femora. There was also a genotype effect 
(trisomic mice were significantly decreased compared euploid littermates) in periosteal 
perimeter [F(1,42) =4.74, p=0.035], I-max [F(1,42) =6.05, p=0.018], and  I-min [F(1,42) =14.51, 
p<0.001].  Mice that received EGCG had a significantly reduced the cortical area [F(1,42) =4.33, 
p=0.044] and cortical thickness  [F(1,42) =5.71, p=0.02]. 
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3.7 Mechanical Testing of Femora 
Ts65Dn mice had significantly decreased structural stiffness [F(1,38) =10.17, p=0.003] 
and strength [F(1,38) =10.82, p=0.002] (ultimate force) in the femora as compared to their 
euploid counterparts (Table 4). In addition, yield force was marginally decreased [F(1,38) =3.87, 
p=0.056]. Treatment with EGCG did not produce positive effects on bone mechanics. Instead, 
EGCG’s effects were detrimental at both the structural and tissue levels  in both trisomic and 
euploid mice. Structural strength (yield force) [F(1,38) =7.59, p=0.009] and ultimate force 
[F(1,38) =9.83, p=0.033]) were significantly decreased with treatment, driving a decrease in 
work to yield  [F(1,38) =4.65, p=0.037].  At the tissue level, ultimate stress was significantly 
decreased [F(1,38) =5.52, p=0.024] and strain to yield was marginally decreased [F(1,38) 
=3.89, p=0.056] in EGCG as compared to water-treated bones. There were no effects of trisomy 
or treatment on any post-yield mechanical properties.  
 
3.8 Dyrk1a Protein Levels and Kinase Activity  
In protein isolated from the cerebellum, Ts65Dn mice receiving water had significantly 
lower Dyrk1a protein than euploid controls (genotype x treatment interaction [F(1,30)=4.51, 
p=0.043] (see Figure 5).  There were no significant effects of genotype or treatment on Dyrk1a 
protein levels in the cerebral cortex, or hippocampus (Table 5).   
[Insert Figure 5] 
In protein isolated from femora of Ts65Dn and euploid mice, EGCG treatment 
significantly lowered kinase activity [main effect of treatment, F(1,39)= 6.68, p=0.014] (see 
Figure 6).  The trend for an effect of genotype did not reach statistical significance (p=0.064).  
No significant main or interactive effects of genotype or treatment were found in kinase activity 
from protein isolated from cerebral cortex, cerebellum or hippocampus (Table 6). 
[Insert Figure 6]  
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4. Discussion 
The aim of this study was to determine whether oral consumption of EGCG in the 
drinking water that yielded a dosage of ~50 mg/kg/day, higher than the dosage used in our 
previous studies (10-20 mg/kg/day) and comparable to the dosage reported by De la Torre et al. 
[45], would improve cognitive and skeletal phenotypes in the Ts65Dn mouse model of DS.  
EGCG failed to appreciably improve outcomes in trisomic mice in most cognitive/behavioral or 
skeletal measures.  One exception to this conclusion was in the MCSF.  EGCG significantly 
increased the risk assessment behavior of the Ts65Dn mice relative to both euploid controls 
together with a non-significant increase above Ts65Dn mice given water (which did not differ 
from controls), suggesting that EGCG treatment resulted in more cautious exploration of novel 
environments in the Ts65Dn mice.  Consistent with this interpretation, EGCG had opposite 
effects on Ts65Dn and euploid mice on risk taking in the MCSF task, confirmed by the 
significant genotype x treatment interaction, in which EGCG decreased risk taking in Ts65Dn 
mice but increased risk taking in euploid controls.  Although the trisomic mice did not have 
significantly higher risk taking than euploid controls, the interactive effect of EGCG on risk taking 
suggests that EGCG may have some beneficial effects for problem behaviors in DS that involve 
behavioral regulation [60].  
No previous studies have been reported assessing the Ts65Dn mouse model using the 
MCSF.  The test has been developed as a multidimensional assessment of distinct behavioral 
phenotypes in a complex environment that is rich with alternatives, in which animals are free to 
move around and explore among various compartments and areas [51].  The MCSF can 
enhance sensitivity to treatments such as brain injury or developmental manipulations that may 
produce changes in internal states that may be expressed as differences in behavioral 
patterning or profiles (e.g., in risk taking, risk assessment, shelter seeking, or exploration) [52-
54, 56].  Our finding that EGCG treatment produces effects in opposite directions for risk taking 
behavior of trisomic and euploid mice raises the intriguing possibility that EGCG may improve 
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the maladaptive behavior expressed in risk-related settings [51, 61], and may have similar 
selective effects on adaptive behavioral regulation in unfamiliar environments in individuals with 
DS [49].  
As is generally reported, the Ts65Dn mice showed significant impairments in acquisition 
of the MWM, emerging over the first five days (of the seven-day training protocol) and 
accompanied by higher levels of thigmotaxis and floating behavior than the euploid mice given 
water.  However, by the last two days there were no significant group differences in path length 
measures.  In contrast to most findings (including our previous report [23]), in the current study 
the probe trial (on the 8th day of testing) yielded no significant group differences.  Since probe 
trial performance typically reflects the strength of memory for the previously learned location, 
the lack of differences is consistent with all groups reaching comparable terminal performance 
on the last two days of acquisition training.  Had the groups been given a probe trial test after 
five days of training (by which time the euploid but not the trisomic mice had acquired the spatial 
learning) rather than after seven training days, it is likely that the probe trial would have revealed 
the trisomic deficit.   
The balance beam test did not yield significant deficits in this study, in contrast to the 
impairments reported in our previous study [62].  In the current study, there was a nonsignificant 
trend toward more slips in the Ts65Dn-water group compared to euploid-water group, but the 
lack of reliable differences in the balance beam suggests it may be susceptible to procedural 
variability.  For example, this study introduced a third, narrower beam test that increased 
difficulty even for the euploid controls and thereby may have reduced the overall sensitivity of 
the task.  In addition, we failed to see any significant differences between euploid and trisomic 
mice in the NOR task.  This is in agreement with our previous finding when mice were given 
20mg/kg/day EGCG for approximately 6 weeks [23].  While other studies have reported a 
trisomic deficit in this task, the many methodological differences across laboratory settings 
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(types of objects used, light intensity, duration of sessions, testing intervals, etc.) may make 
NOR outcomes perhaps a less reliable or generalizable indicator of cognitive deficits. 
The treatment with ~50/mg/kg day EGCG for 7 weeks caused unfavorable effects in 
bone structure and mechanical properties in Ts65Dn and euploid mice, including cortical area, 
cortical thickness, yield force, ultimate force, work to yield, ultimate stress, and strain to yield.  
Ts65Dn mice showed deficits in trabecular bone (percent bone volume, separation and number) 
cortical bone geometry (total cross sectional area, cortical area, cortical thickness, periosteal 
perimeter), I-max, and I-min and bone strength (ultimate force and stiffness), that were either not 
improved or were reduced by EGCG treatment.  No post-yield mechanical properties were 
impacted by either trisomy or EGCG treatment.  Aside from the change in ultimate stress with 
treatment, all mechanical changes were in whole bone properties which suggest that it was 
mostly changes in bone size/geometry that drove mechanical deficits as compared to inferior 
tissue quality.  Similar skeletal deficits including decreases in ultimate force and stiffness were 
quantified in femurs from euploid mice with only one copy of Dyrk1a [63].   
In contrast, our previous study using a three week administration of EGCG 
(~10mg/kg/day) showed improved skeletal deficits including femoral bone mineral density, 
percent trabecular bone volume, trabecular number and trabecular thickness in Ts65Dn mice 
[63].  These results suggest that in bone, there may be an “inverted U” function of optimal 
Dyrk1a activity, such that an optimal range of activity is necessary to achieve maximum skeletal 
strength, and falling below the threshold (as with high doses of EGCG) or exceeding an upper 
boundary (as with excess activity in trisomy) may be detrimental to bone strength.  Additionally, 
when we treated Ts65Dn mice with two EGCG-containing supplements that delivered lower 
daily dosages (3-4 mg/kg/day EGCG), we found that the structure of the bone improved but the 
strength decreased [44].  These data suggested that other catechins or a combination of 
catechins could have a detrimental effect on skeletal strength.  Our outcomes are among the 
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first to report apparently adverse effects of EGCG treatment in association with DS phenotypes 
in Ts65Dn as well as in normal mice. 
This study is one of only a few that has quantified Dyrk1a protein levels and kinase 
activity in brain and/or bone of Ts65Dn mice after undergoing EGCG treatment, and only a few 
studies have examined Dyrk1a protein levels in Ts65Dn mice in specific brain regions.  We 
found that trisomic mice displayed decreased Dyrk1a protein levels in the cerebellum, but there 
were no significant effects of trisomy or EGCG treatment on Dyrk1a protein levels in the 
cerebral cortex or the hippocampus.  In contrast, Ahmed et al. [64] reported increased Dyrk1a 
protein levels in the hippocampus, cortex and cerebellum of older Ts65Dn mice (~5-8 months of 
age).  In addition, increased Dyrk1a protein levels in the hippocampus were found in ~3-4 
month-old Ts65Dn mice [65].  The discrepancies between these findings and those of the 
current study may reflect differences in age, prior experience (extensive behavioral testing in 
our study) or other methodological differences, and highlight the need for a systematic analysis 
of potential changes in the spatial and temporal expression of Dyrk1a protein across the 
lifespan of Ts65Dn mice.   
The relative lack of consistent matches between Dyrk1a brain protein levels and kinase 
activity measures—across trisomic and euploid mice, with and without EGCG treatment—
suggests that the kinase assay may not be specific for Dyrk1a kinase activity but may be 
indicative of broader kinase activity.  We did find a significant EGCG-induced reduction in 
kinase activity in femur regardless of phenotype, and this effect of EGCG treatment was 
associated with adverse changes in femora cortical structure and overall skeletal strength. 
Taken together, our current results indicate that the reduction in kinase activity in the 
appendicular skeleton after 7 weeks of treatment with ~50 mg/kg/day EGCG was associated 
with detrimental effects on bone structure and strength in trisomic and normal mice, rather than 
the beneficial effects seen with our previous lower-dose treatments.  In addition, our finding that 
EGCG did not significantly alter kinase activity in any of the brain regions suggests that EGCG 
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treatment either induced compensatory effects on brain Dyrk1a activity (or on activity of other 
kinases that phosphorylate the Woodtide substrate, discussed below) or that bioavailability of 
EGCG was less in brain than in bone. 
The kinase activity assay used herein that was modified after Bui et al. [55] has been 
reported to detect Dyrk1a kinase activity levels.  The Dyrk1a substrate, 5-carboxyfluorescein-
Woodtide, is derived from amino acids 321-332 of the FOXO1 transcription factor [66] and was 
used to determine kinase activity from proteins isolated from the cerebral cortex, cerebellum, 
hippocampus, and femur. One important consideration is that in addition to being 
phosphorylated by Dyrk1a, this protein fragment also is phosphorylated by CK1 and may be 
phosphorylated by other kinases [66].  Although the reduction of kinase activity observed in the 
femur after EGCG treatment may be attributed to Dyrk1a inhibition, other kinases that 
phosphorylate Woodtide may be present and inhibited by EGCG.  This possibility highlights the 
need for future studies to identify the specific and independent contribution of Dyrk1a 
phosphorylation of the target peptide. 
Our findings highlight important remaining gaps in knowledge about the extent to which 
EGCG holds potential therapeutic value for DS phenotypes and which need to be addressed in 
future studies in mouse models of DS. Preclinical models need to focus on and clarify four 
critical aspects of EGCG treatment: 1) the timing and duration of EGCG administration, 2) the 
optimal dosage of administration, 3) the type of EGCG-containing supplement that is 
administered, and 4) the mechanisms that may account for any therapeutic effects of EGCG, 
including determining whether effects are mediated by inhibition of Dyrk1a.   
The timing and duration of EGCG administration may determine the effectiveness of the 
treatment.  Others have treated with EGCG beginning in adulthood, whereas this and our 
previous studies began treatment in adolescence.  When 3-month-old Ts65Dn mice were given 
an EGCG-containing supplement (Life Extension® Mega Green Tea Extract, Lightly Caffeinated) 
in drinking water, improvements in cognitive behaviors was reported [45]. Combining treatment 
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with an EGCG-containing supplement and environmental enrichment resulted in improvement in 
hippocampal-dependent MWM task in older 5-6 month-old mice [61].  Several studies have 
assessed EGCG treatment early in development.  Treatment with pure EGCG during perinatal 
stages on Ts65Dn mice (25mg/kg via subcutaneous injection on PD 3-15) yielded an increase 
in neurogenesis and related proteins immediately after treatment cessation on PD 15, but these 
cellular effects were transient and were not evident at PD 45 and did not significantly improve 
hippocampal dependent learning and memory in trisomic mice [48].  Pregnant Ts65Dn mothers 
treated with 400mg/kg/day EGCG on embryonic days (E) 7 and 8 via oral gavage and saw 
improvements in the E9.5 1st pharyngeal arch size and cell number and in the size and shape of 
the cranial vault in 6 week old mice [47].  Thus, the age at which the mice are administered an 
EGCG-containing therapeutic appears to be a critical factor in the efficacy of targeted 
therapeutics.  Taken together, these data suggest that a pre- or perinatal EGCG treatment, 
perhaps combined with other behaviorally-based therapies during development, may be the 
most effective approaches for EGCG therapeutics for DS phenotypes. 
It is essential to identify potential dose-related differences in outcomes with EGCG 
treatment, in part because different doses of EGCG have been hypothesized to affect 
neurocognitive phenotypes differently.  For example, it has been reported that a low 
concentration of EGCG produces an anti-apoptotic effect to protect against neurotoxicity and a 
high concentration of EGCG induces a pro apoptotic effect [67].  Our laboratory has yet to find 
significant improvement in cognitive tasks after various doses of pure EGCG administration of 3-
7 weeks to adolescent Ts65D mice (10, 20, and 50mg/kg/day).  A perinatal dose of 25mg/kg did 
not improve hippocampal dependent learning and memory in trisomic mice [48].  These findings 
suggest that varying doses of pure EGCG administered to Ts65Dn mice for different periods of 
time have limited or no effectiveness in improving cognitive deficits.   
One important consideration is that our studies finding almost no therapeutic benefit 
used pure EGCG, whereas other laboratories that use EGCG-containing supplements that 
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include other catechins and unknown components have reported beneficial effects on cognitive 
behavior [45].  This suggests that other molecules found in these supplements may be 
contributing to these reported beneficial effects.  We previously used a radioactive-based 
Dyrk1a activity assay (based on activity of antibody-specific isolation of Dyrk1a protein) to show 
that Dyrk1a activity in cerebellum, hippocampus or femur was not significantly affected by a 
three-week adolescent treatment with ~10 mg/kg/day EGCG [23, 26].  In contrast, De la Torre 
and colleagues [45] used a similar radioactivity assay of Dyrk1a kinase activity and found 
significant reductions in Dyrk1a activity in the hippocampus of transgenic TgDyrk1a mice (that 
have an increased copy number of Dyrk1a with no other trisomic genes) after treatment for 1 
month in adulthood.  Calculations of the amount of EGCG administered in any dosing regimen 
must account for the differences in the amount of EGCG in the various EGCG-containing 
supplements used, amount of degradation, and should also determine the amount of the other 
catechins included in those supplements.  It should be determined whether other catechins (or 
other molecules) present in the EGCG-containing supplements could be influencing the 
observed behavioral improvements.  Identifying the role of these other catechins in therapeutic 
outcomes in preclinical mouse models will be important to identify the optimal use of 
supplements as potential therapeutic nutraceuticals.  This information will allow for better 
comparisons across studies, and the development more targeted therapeutics.  Questions also 
remain about the exact bioavailability and blood-brain-barrier penetration of EGCG, given the 
lack of behavioral improvements and failure to inhibit brain kinase activity with pure EGCG 
administration in this study. 
Finally, if the therapeutic effects of EGCG are mechanistically caused by inhibition of 
Dyrk1a, then it will be important to demonstrate conclusively that Dyrk1a overexpression and/or 
increased Dyrk1a activity in specific tissues or specific brain regions can be causally linked to 
specific trisomic phenotypes. The possibility that enduring adverse effects resulting from a time- 
and spatially-limited period of excessive Dyrk1a activity must also be considered.  We did not 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
detect significant differences in kinase activity between adult euploid and Ts65Dn mice in three 
brain regions.  In addition, we did not detect any group differences in Dyrk1a protein levels in 
either the cerebral cortex or hippocampus, and found the counterintuitive result that Ts65Dn 
mice had significantly lower Dyrk1a protein expression compared to euploid controls in the 
cerebellum.  If confirmed, this could mean that Dyrk1a overexpression/kinase activity is 
developmentally regulated and its status in adulthood may not correlate with or cause observed 
adult DS phenotypes. It may be that overexpression/over activity of Dyrk1a at an earlier age or 
critical period is responsible for these phenotypes or that other triplicated genes may be 
responsible for these deficits.  The prospect remains that Dyrk1a is a viable target for improving 
DS phenotypes, but additional information about spatiotemporal expression of Dyrk1a and 
Dyrk1a inhibitors with increased bioavailability and well-characterized pharmacological activity 
in the brain in preclinical studies using mouse models of DS must be ascertained. 
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Figure 1.  Behavioral Study Timeline.  Timeline for the current study beginning shortly after weaning 
(PD22).  Animals received EGCG or water treatment throughout the behavioral testing, even on rest 
days. 
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Eu+Water, n=19 
 
 
 
 
 
 
 
 
Figure 2a.  MCSF Total Entries.  Both Euploid (Eu) and Trisomic (Ts) mice increased the number of 
entries from Day 1 to Day 2.  As indicated by (*), Eu+Water, Ts+Water, and Ts+EGCG groups had a 
significantly higher number of total entries on Day 2.  Data are represented by mean ± SEM.   
Figure 2b.  MCSF Risk Assessment Behavior.  The Trisomic (Ts) mice exhibited higher risk 
assessment behavior than the Euploid (Eu) mice (data collapsed across both days).  As indicated by the 
(*), the Ts+EGCG group displayed significantly higher risk assessment behavior compared to both 
euploid groups.  Data are represented by mean ± SEM.   
Eu+Water, n=19 
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Figure 2c.  MCSF Risk Taking Behavior.  There was a significant genotype x treatment interaction. 
Data are collapsed across days since there were no effects of day.  Note that EGCG treatment had 
opposing effects on euploid and trisomic mice. Data are represented by mean ± SEM  
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Figure 3a.  MWM Acquisition Path Length.  Acquisition in the Morris water maze spatial learning task 
by the Euploid (Eu) and Trisomic (Ts) groups.  Each line represents the average path length (meters) for 
each acquisition day.  All groups showed a decrease in latency over training days.  However, trisomic 
mice of both treatment groups displayed higher path lengths versus the euploid groups (main effect of 
genotype, indicated by (*).  Insert graph represents the total path length summed across all 7 acquisition 
days.  Both trisomic groups exhibited increased total latency versus euploid-water controls (as indicated 
by the *).  LSD post-hoc analysis revealed a significant increase in Trisomic + Water and Trisomic 
+EGCG latencies as compared to Euploid + Water mice (as indicated by the ×).  Data are represented as 
mean ± SEM.    
Figure 3b.  MWM Acquisition Latency.  Seconds spent locating the hidden platform by the Euploid (Eu) 
and Trisomic (Ts) groups.  Each line represents the average time (latency) to find the hidden platform for 
each training day.  All groups showed significant reductions in latencies over days (main effect of day).  
However, trisomic mice were significantly impaired versus controls (day x genotype interaction, p=0.041). 
LSD post-hoc analysis revealed a significant increase in Trisomic + Water and Trisomic +EGCG latencies 
as compared to Euploid + Water (as indicated by the ×), or increases in Trisomic + EGCG latencies 
versus Euploid + Water mice (as indicated by the +).    Data are represented as mean ± SEM.    
Figure 3c.  MWM Acquisition Thigmotaxic Behavior.  Percent of time spent in thigmotaxis (within 25.4 
cm of the wall) by the Euploid (Eu) and Trisomic (Ts) groups.  Each line represents the average percent 
of time for each acquisition day.  There was an overall decrease in thigmotaxic behavior over training 
days, most evident in the Euploid-water group; however, mice receiving EGCG displayed higher 
thigmotaxis versus the water groups (main effect of treatment, p=0.039), due mainly to the increased 
thigmotaxic behavior of the Euploid-EGCG group relative to the euploid-water group.  Data are 
represented as mean ± SEM.    
Figure 3d.  MWM Acquisition Floating Behavior.  Seconds spent floating by the Euploid (Eu) and 
Trisomic (Ts) groups.  Each line represents the average time (seconds) floating for each acquisition day.  
Trisomic mice displayed significantly less reduction in floating behavior over days than the euploid mice 
(day x genotype interaction, p=0.017).  Data are represented as mean ± SEM. 
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Figure 4.  MWM Probe Trial.  Probe trial performance of Euploid (Eu) and Trisomic (Ts) mice of the two 
treatment groups on the probe trial (Day 8).  The (*) comparing the Target and Non-target times of the 
euploid groups indicates a significant spatial bias for the Target location for both euploid groups ; the 
similar trend for the trisomic groups did not reach statistical significance. Bars represent the average time 
spent in the target and non-target quadrant, with error bars represented as SEM. 
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Figure 5.   Dyrk1a Protein Levels-Cerebellum.  Dyrk1a protein levels in the cerebellum of ~9-week old 
mice given 6 weeks of treatment with water or EGCG (mean ± SEM).  Ts65Dn mice receiving water had 
significantly less Dyrk1a protein that euploid-water controls (as indicated by the *, genotype x treatment 
interaction, p=0.043). 
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Figure 6.   Kinase activity-Femur.  Kinase activity in the femur of ~9-week old mice given 6 weeks of 
treatment with water or EGCG (mean ± SEM). Mice receiving EGCG treatment had significantly lower 
kinase activity than mice receiving water (main effect of treatment p<0.05).  
  
Eu+Water (n=14) 
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Table 1. The behavioral phenotypes that were assessed from the MCSF maze (first column).  
Each phenotype analysis included specific behavioral measures obtained from the scoring with 
Observer XT and analyzed as described in the text. 
Behavioral 
Phenotype 
Measures Comprising Behavioral Phenotypes  
Total 
Entries 
Frequency 
of TotCorr 
entries 
Frequency 
of hurdle 
entries 
Frequency 
of DCR 
entries 
Frequency 
of Slope 
entries 
Frequency 
of Bridge 
entries 
Frequency 
of center 
circle 
entries 
Frequency 
of center 
entries 
Exploratory 
Behavior 
Duration 
of hurdle 
visits 
Hurdle 
duration 
per visit 
Number of 
photocell 
counts 
Latency to 
initial 
slope visit 
Latency to 
initial 
hurdle 
visit 
Center 
Duration 
per visit 
  
Risk 
Assessment 
Latency to 
leave 
center 
arena 
Slope 
duration 
per visit 
(Latency 
to initial 
bridge 
visit)-
(Latency 
to initial 
slope visit) 
        
Risk-taking 
Behavior 
Duration 
of bridge 
visits 
Bridge 
duration 
per visit 
Duration 
of center 
circle 
visits 
Center 
circle 
duration 
per visit 
      
Shelter 
Seeking 
Frequency 
of dark 
corner 
room 
Duration 
of dark 
corner 
room 
Duration 
per visit of 
dark 
corner 
room 
Latency to 
initial DCR 
visit 
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Table 2. Average starting weight, final weight and EGCG consumption (corrected for 
degradation) for the respective tested groups. 
Group N 
Body 
Weight 
(P24) 
Body 
Weight 
(P68) 
Average 
EGCG 
Consumption 
(mg/kg/day) 
Eu+Water 19 
15.9 ± 
0.9 
28.4 ± 
0.6 
- 
Eu+EGCG 18 
15.2 ± 
0.9 
27.4 ± 
0.8 
48.7 ± 1.1 
Ts+Water 13 
12.4 ± 
0.3 
22.8 ± 
0.8 
- 
Ts+EGCG 15 
11.8 ± 
0.6 
23.9 ± 
0.8 
52.9 ± 1.4 
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Table 3.  
 
  
 Skeletal Structure Euploid 
(n=14) 
Ts65Dn 
(n=10) 
Ts65Dn + EGCG 
(n=12) 
Euploid + EGCG 
(n=11) 
Trabecular Bone 
Bone mineral density 
(BMD) (g/cm
2
)
A
 
0.248 ±  0.009 0.35 ± 0.013 0.222 ± 0.011 0.261 ± 0.010 
Percent bone volume 
(BV/TV) (%)
A
 
30.26 ± 1.38 27.14 ± 2.01 26.10 ± 1.18 30.39 ± 1.34 
Trabecular thickness 
(Tb.Th) (µ) 
0.072 ± 0.001 0.072 ± 0.002 0.071 ± 0.001 0.074 ± 0.001 
Trabecular separation 
(Tb.Sp) (mm)
 A
 
0.145 ± 0.005 0.166 ± 0.009 0.170 ± 0.007 0.150 ± 0.006 
Trabecular number 
(Tb.N) (1/mm)
 A
 
4.204 ± 0.165 3.756 ± 0.220 3.663 ± 0.155 4.103 ± 0.162 
Cortical Bone 
Total cross sectional area 
(CSA) (mm
2
)
A
 1.73 ± 0.05 1.57 ± 0.06 1.51 ± 0.03 1.66 ± 0.05 
Marrow Area (mm
2
) 
0.71 ± 0.03 0.67 ± 0.04 0.67 ± 0.02 0.71 ± 0.03 
Cortical Area  (mm
2
)
A,B
 
1.03 ± 0.03 0.90 ± 0.04 0.85 ± 0.02 0.95 ± 0.03 
Cortical Thickness (mm)
A,B
 
0.27 ± 0.01 0.25 ± 0.01 0.23 ± 0.01 0.25 ± 0.01 
Periosteal BS (mm) 
5.63 ± 0.07 5.37 ± 0.10 5.36 ± 0.07 5.46 ± 0.07 
Endocortical BS (mm) 
3.70 ± 0.07 3.61 ± 0.11 3.63 ± 0.06 3.72 ± 0.06 
I max (mm
4
)
A
 0.30 ± 0.02 0.24 ± 0.02 0.23 ± 0.01 0.26 ± 0.01 
I min (mm
4
)
A
 0.14 ± 0.01 0.11 ± 0.01 0.10 ± 0.00 0.13 ± 0.01 
Tissue mineral density 
TMD (g/cm 3^ HA) 
1.21 ± 0.02 1.22 ± 0.02 1.20 ± 0.01 1.21 ± 0.02 
A Main effect of genotype, B Main effect of treatment. Parameter values are listed as averages 
± (SEM). 
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Table 4.  
Mechanical 
Testing 
Euploid Ts65Dn 
Ts65Dn 
+ 
EGCG 
Euploid 
+ 
EGCG 
(n=13) (n=9) (n=10) (n=10) 
Yield Force 
(N)
B
 
12.62 ± 
0.48 
10.40 ± 
0.82 
9.24 ± 
0.72 
9.83 ± 
0.89 
Ultimate 
Force (N)
A,B
 
18.91 ± 
1.14 
14.38 ± 
1.14 
12.19 ± 
0.81 
14.55 ± 
0.90 
Displacement 
to Yield (µm) 
136.54 ± 
11.22 
138.00 ± 
6.05 
135.40 ± 
7.70 
115.40 ± 
8.57 
Postyield 
Displacement 
(µm) 
688.85 ± 
157.27 
721.89 ± 
234.49 
831.80 ± 
118.31 
838.60 ± 
153.17 
Total 
Displacement 
(µm) 
825.38 ± 
164.15 
859.89 ± 
234.20 
967.20 ± 
121.95 
954.00 ± 
155.56 
Stiffness 
(N/mm)
A
 
119.04 ± 
9.09 
92.65 ± 
9.08 
82.48 ± 
5.39 
111.42 ± 
9.45 
Work to Yield 
(mJ)
B
 
1.01 ± 
0.11 
0.81 ± 
0.08 
0.75 ± 
0.09 
0.68 ± 
0.08 
Postyield 
Work (mJ) 
8.51 ± 
1.11 
7.61 ± 
2.26 
7.35 ± 
1.25 
8.10 ± 
1.49 
Total Work 
(mJ) 
9.52 ± 
1.12 
8.42 ± 
2.28 
8.09 ± 
1.32 
8.78 ± 
1.53 
Yield Stress 
(MPa) 
123.74 ± 
6.54 
120.06 ± 
7.40 
119.68 ± 
9.43 
103.89 ± 
9.81 
Ultimate 
Stress 
(MPa)
B
 
181.31 ± 
7.56 
165.05 ± 
5.64 
156.57 ± 
8.27 
152.12 ± 
9.32 
Strain to 
Yield ()
B
 
12394.20 
± 880.50 
12113.17 
± 544.77 
11272.60 
± 646.70 
10312.85 
± 710.30 
Total Strain 
() 
74008.75 
± 
13842.05 
77113.80 
± 
22175.14 
80917.37 
± 
10486.08 
85632.10 
± 
14167.40 
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Modulus 
(GPa) 
12.26 ± 
0.55 
12.03 ± 
0.57 
12.75 ± 
0.73 
12.58 ± 
0.57 
Resilience 
(MPa) 
0.94 ± 
0.14 
0.83 ± 
0.08 
0.81 ± 
0.10 
0.65 ± 
0.08 
Toughness 
(MPa) 
8.68 ± 
1.12 
7.98 ± 
1.61 
8.65 ± 
1.35 
8.50 ± 
1.60 
  A Main effect of genotype, B Main effect of treatment. 
Parameter values are listed as averages ± (SEM). 
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Table 5. Ts65Dn mice receiving water had significantly less Dyrk1a protein that euploid-water 
controls (genotype x treatment interaction, p=0.043).  There were no significant effects of 
genotype or treatment on Dyrk1a protein levels in the cerebral cortex, or hippocampus.  Data 
are represented as mean ± SEM fold protein change, relative to Euploid + Water control mean. 
 
 
 
  
 Group Cerebral 
Cortex Mean 
Fold Change  
Group Hippocampus 
Mean Fold 
Change 
Group Cerebellum 
Mean Fold 
Change 
Eu+Water (n=10) 1.00 ± 0.20 Eu+Water (n=9) 0.99 ± 0.06 Eu+Water (n=9) 1.05 ± 0.15 
Eu+EGCG (n=10) 1.02 ± 0.25 Eu+EGCG (n=10) 1.45 ± 0.19 Eu+EGCG (n=9) 0.68 ± 0.13 
Ts+Water (n=9) 1.04 ± 0.28 Ts+Water (n=5) 1.16 ± 0.20 Ts+Water (n=5) 0.63 ± 0.12 
Ts+EGCG (n=6) 0.83 ± 0.14 Ts+EGCG (n=4) 1.37 ± 0.36 Ts+EGCG (n=7) 0.85 ± 0.18 
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Table 6. There were no significant effects of genotype or treatment on Dyrk1a activity in the 
cerebral cortex, cerebellum and hippocampus.  Data is represented as the area under the curve 
of the fluorescence emission ± SEM. 
 
 
 
 
 
  
  Cerebral Cortex Cerebellum Hippocampus 
Eu+Water (n=8) 143.2 ± 15.0 399.3 ± 21.8 342.6 ± 22.6 
Eu+EGCG (n=8) 126.4 ± 14.0 404.9 ± 22.5 290.6 ± 34.6 
Ts+Water (n=6) 171.2 ± 18.0 373.8 ± 34.2 287.7 ± 36.8 
Ts+EGCG (n=9) 148.8 ± 17.7 424.2 ± 20.7 301.5 ± 21.3 
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Highlights 
 EGCG treatment produces minimal improvement in cognitive phenotypes in DS mice 
 DS mice treated with 50 mg/kg/day EGCG displayed unfavorable bone phenotypes 
 Dyrk1a protein and kinase activity levels revealed need to understand effects of EGCG 
 Significant gaps remain regarding potential therapeutic value of EGCG for DS traits 
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